Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The future of affordable cancer immunotherapy.
Schaft N, Dörrie J, Schuler G, Schuler-Thurner B, Sallam H, Klein S, Eisenberg G, Frankenburg S, Lotem M, Khatib A. Schaft N, et al. Among authors: frankenburg s. Front Immunol. 2023 Sep 6;14:1248867. doi: 10.3389/fimmu.2023.1248867. eCollection 2023. Front Immunol. 2023. PMID: 37736099 Free PMC article. Review.
Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions.
Hajaj E, Zisman E, Tzaban S, Merims S, Cohen J, Klein S, Frankenburg S, Sade-Feldman M, Tabach Y, Yizhak K, Navon A, Stepensky P, Hacohen N, Peretz T, Veillette A, Karni R, Eisenberg G, Lotem M. Hajaj E, et al. Among authors: frankenburg s. Cancer Immunol Res. 2021 Jun;9(6):637-650. doi: 10.1158/2326-6066.CIR-20-0800. Epub 2021 Mar 24. Cancer Immunol Res. 2021. PMID: 33762352
SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint.
Hajaj E, Eisenberg G, Klein S, Frankenburg S, Merims S, Ben David I, Eisenhaure T, Henrickson SE, Villani AC, Hacohen N, Abudi N, Abramovich R, Cohen JE, Peretz T, Veillette A, Lotem M. Hajaj E, et al. Among authors: frankenburg s. Elife. 2020 Mar 3;9:e52539. doi: 10.7554/eLife.52539. Elife. 2020. PMID: 32122464 Free PMC article.
Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.
Lotem M, Merims S, Frank S, Hamburger T, Nissan A, Kadouri L, Cohen J, Straussman R, Eisenberg G, Frankenburg S, Carmon E, Alaiyan B, Shneibaum S, Ozge Ayyildiz Z, Isbilen M, Mert Senses K, Ron I, Steinberg H, Smith Y, Shiloni E, Gure AO, Peretz T. Lotem M, et al. Among authors: frankenburg s. J Immunol Res. 2016;2016:8121985. doi: 10.1155/2016/8121985. Epub 2016 May 18. J Immunol Res. 2016. PMID: 27294163 Free PMC article. Clinical Trial.
71 results